Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review

Thrombotic arteriopathy has been implicated in the pathophysiology of pulmonary arterial hypertension (PAH). However, the role of anticoagulants in the treatment of PAH is uncertain. Through a qualitative systematic review of epidemiological studies, the effectiveness of anticoagulation therapy with warfarin on survival was evaluated in patients with PAH. MEDLINE (1966 to November 2005), EMBASE (1966 to November 2005), bibliographies of included studies and published reviews were searched without language restriction. Epidemiological studies evaluating the effectiveness of warfarin in PAH were included. Studies had to report mortality as an outcome. Seven observational studies evaluating the effectiveness of warfarin comprising 488 patients were identified. Five studies support the effectiveness of anticoagulation therapy, whereas two do not. Data from observational studies suggest that anticoagulation therapy may be an effective intervention in pulmonary arterial hypertension. However, given the methodological limitations and the small number of existing observational studies, a randomised controlled trial is needed in order to definitively address this important clinical issue.

[1]  David M. Smith,et al.  Risk of major hemorrhage for outpatients treated with warfarin , 1998, Journal of General Internal Medicine.

[2]  C. Ricachinevsky,et al.  Treatment of pulmonary arterial hypertension. , 2006, Jornal de pediatria.

[3]  Christine Carrico,et al.  EVOLUTION AND OUTCOMES OF A RAPID RESPONSE TEAM , 2006 .

[4]  Sanjay Mehta,et al.  Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. , 2006, Chest.

[5]  R. Barst,et al.  Sitaxsentan: a novel endothelin-A receptor antagonist for pulmonary arterial hypertension , 2005, Expert review of cardiovascular therapy.

[6]  D. Badesch,et al.  Evaluation and Management of the Patient with Pulmonary Arterial Hypertension , 2005, Annals of Internal Medicine.

[7]  Mark Crowther,et al.  Systematic overview of warfarin and its drug and food interactions. , 2005, Archives of internal medicine.

[8]  J. Dimarco,et al.  Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. , 2005, American heart journal.

[9]  D. Pennell,et al.  Cardiovascular magnetic resonance of left ventricular pseudoaneurysm , 2005, Heart.

[10]  H. Morita,et al.  Risk of alveolar hemorrhage in patients with primary pulmonary hypertension--anticoagulation and epoprostenol therapy. , 2005, Circulation journal : official journal of the Japanese Circulation Society.

[11]  R. Barst,et al.  New predictors of outcome in idiopathic pulmonary arterial hypertension. , 2005, The American journal of cardiology.

[12]  K. Fahrbach,et al.  Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. , 2004, Chest.

[13]  D. Mccrory,et al.  Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines , 2004 .

[14]  J. Knowles,et al.  Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. , 2004, Circulation.

[15]  H. Dincer,et al.  Current Management of Pulmonary Hypertension , 2004 .

[16]  D. Mccrory,et al.  Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.

[17]  H. Halkin,et al.  Mechanism of warfarin potentiation by amiodarone: Dose — and concentration — Dependent inhibition of warfarin elimination , 2004, European Journal of Clinical Pharmacology.

[18]  Lisa M. Murphey,et al.  Bosentan and Warfarin Interaction , 2003, The Annals of pharmacotherapy.

[19]  F. Morell,et al.  Estudio clínico-hemodinámico y tratamiento de 44 pacientes con hipertensión pulmonar primaria , 2002 .

[20]  David R. Jones,et al.  Bayesian methods in health technology assessment: a review. , 2000, Health technology assessment.

[21]  M Blettner,et al.  Traditional reviews, meta-analyses and pooled analyses in epidemiology. , 1999, International journal of epidemiology.

[22]  A. Lopes,et al.  Circulating von Willebrand factor antigen as a predictor of short-term prognosis in pulmonary hypertension. , 1998, Chest.

[23]  A. Duchini,et al.  Gastrointestinal hemorrhage in patients with systemic sclerosis and CREST syndrome , 1998, American Journal of Gastroenterology.

[24]  R. Beyth,et al.  Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. , 1998, The American journal of medicine.

[25]  M J Campbell,et al.  Clinical significance not statistical significance: a simple Bayesian alternative to p values. , 1998, Journal of epidemiology and community health.

[26]  P. Rolan,et al.  Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. , 2003, British journal of clinical pharmacology.

[27]  H P Gurtner,et al.  The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. , 1997, Chest.

[28]  Perova Nv,et al.  The characteristics of the blood lipid transport system in the disabled with lost lower extremities , 1997 .

[29]  I. Chazova,et al.  [The effect of long-term Fraxiparin treatment on hemostasis in patients with primary pulmonary hypertension]. , 1997, Terapevticheskii arkhiv.

[30]  S. Fihn,et al.  The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin , 1996, Annals of Internal Medicine.

[31]  J. Lettieri,et al.  Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  J. Golden,et al.  Do patients with primary pulmonary hypertension develop extensive central thrombi? , 1995, Circulation.

[33]  A. Lopes,et al.  Abnormal multimeric and oligomeric composition is associated with enhanced endothelial expression of von Willebrand factor in pulmonary hypertension. , 1993, Chest.

[34]  N. Aikawa,et al.  Role of 5-hydroxytryptamine in the progression of monocrotaline induced pulmonary hypertension in rats. , 1993, Cardiovascular research.

[35]  J. Mlczoch,et al.  [Aminorex-induced, plexogenic pulmonary arteriopathy: 25 years later!]. , 1993, Zeitschrift fur Kardiologie.

[36]  T Takishima,et al.  Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension. , 1993, Japanese circulation journal.

[37]  B. Groves,et al.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.

[38]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[39]  M. Gibaldi,et al.  The mechanism of the interaction between amiodarone and warfarin in humans , 1992, Clinical pharmacology and therapeutics.

[40]  A. Jaffe,et al.  Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. , 1990, Circulation.

[41]  M. Klauber,et al.  Effect of erythromycin in patients receiving long-term warfarin therapy. , 1989, Clinical pharmacy.

[42]  W. Trager,et al.  Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans , 1987, Clinical pharmacology and therapeutics.

[43]  L. Hoyer,et al.  von Willebrand factor abnormalities in primary pulmonary hypertension. , 1987, The American review of respiratory disease.

[44]  D. Langleben,et al.  Decreased half-life of fibrinogen in primary pulmonary hypertension. , 1985, Thrombosis research.

[45]  W. Edwards,et al.  Primary pulmonary hypertension: a histopathologic study of 80 cases. , 1985, Mayo Clinic proceedings.

[46]  V. Fuster,et al.  Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.

[47]  C. Wagenvoort.  Lung biopsy specimens in the evaluation of pulmonary vascular disease. , 1980, Chest.

[48]  R. O'Reilly,et al.  Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans. , 1979, Annals of internal medicine.

[49]  R. O'Reilly.  The stereoselective interaction of warfarin and metronidazole in man. , 1976, The New England journal of medicine.

[50]  R. Rokseth,et al.  Primary pulmonary hypertension with emphasis on its etiology and treatment. , 2009, Acta medica Scandinavica.

[51]  D. Wilcken,et al.  Obliterative Pulmonary Hypertension and Thrombo-embolism* , 1963, British medical journal.

[52]  D. Wilcken,et al.  Anticoagulant treatment of obliterative pulmonary hypertension. , 1960, Lancet.

[53]  P. Davison,et al.  Chronic cor pulmonale due to silent pulmonary embolism. , 1956, Lancet.